Mechanisms of immune escape and extramedullary tropism in leukemia cutis
Abstract
Abstract The mechanisms that lead to extramedullary tropism of acute myeloid leukemia (eAML) remain obscure and no specific therapeutic approaches for this entity exist. Because the long-term survival of eAML is poor, a deeper understanding of the immune microenvironment and leukemia phenotypes underlying this entity is warranted. Here, we performed bulk and single-cell transcriptome profiling of 23 eAML biopsies from 10 patients with isolated extramedullary disease in skin and subcutaneous tissue. Unlike normal healthy skin, we found leukemia cutis to be heavily immune infiltrated; in extramedullary relapse after allogeneic stem cell transplantation, >90% of T/natural killer cells were donor derived. eAML-associated T cells expressed a clear signature of T-cell exhaustion, dissimilar to leukemia-associated immune populations in bone marrow relapse (n = 7) but related to acute and chronic skin inflammation. Furthermore, HLA class II was downregulated in 4 of 7 leukemia cutis specimens, consistent with an immune escape phenotype in eAML. Extramedullary and bone marrow–resident leukemia cells differed with regard to the expression of 8 homing receptor molecules (ICAM1 [encoding CD54], PECAM1 [CD31], ITGA4, ITGA6, ITGAL, ITGB4, ITGA5, and ITGAV). Serial samples obtained from 1 leukemia cutis throughout consecutive immune checkpoint blockade with ipilimumab followed by nivolumab showed a consistently high degree of overlap between local and circulating T-cell receptor sequences, suggesting that only a minority of eAML-associated T cells are leukemia specific. Our analysis reveals eAML to associate with complex changes in leukemia and T-cell gene expression profiles that suggest multiple potential avenues for therapeutic targeting.
Article Details
Authors (17)
Livius Penter
Katie Maurer
Nicoletta Cieri
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Wesley S. Lu
6Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA
Haoxiang Lyu
2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
Mischa Selig
2Department of Hematology, Oncology, and Cancer Immunology, Campus Virchow-Klinikum, Berlin, Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
Maria Joosten
Jana Ihlow
2Institute of Pathology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
Shuqiang Li
Kenneth J. Livak
Lars Bullinger
Jerome Ritz
Dana–Farber Cancer Institute, Boston
Pavan Bachireddy
8MD Anderson Cancer Center, Houston, TX
Matthew S. Davids
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
Jacqueline S. Garcia
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Robert J. Soiffer
Dana-Farber Cancer Institute
Catherine J. Wu